

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis and Biological Evaluation of Halo-neplanocin A as Novel Mechanism-Based Inhibitors of S-Adenosylhomocysteine Hydrolase

Lak Shin Jeong^a; Hyung Ryong Moon^a; Jae Gyu Park^a; Dae Hong Shin^a; Won Jun Choi^a; Kang Man Lee^a; Hea Ok Kim^b; Moon Woo Chun^c; Hee-Doo Kim^d; Joong Hyup Kim^e

^a College of Pharmacy, Ewha Womans University, Seoul, Korea ^b Division of Chemistry and Molecular Engineering, Seoul National University, Seoul, Korea ^c College of Pharmacy, Seoul National University, Seoul, Korea ^d College of Pharmacy, Sookmyung Women's University, Seoul, Korea ^e Korea Institute of Science and Technology, Seoul, Korea

Online publication date: 09 August 2003

To cite this Article Jeong, Lak Shin , Moon, Hyung Ryong , Park, Jae Gyu , Shin, Dae Hong , Choi, Won Jun , Lee, Kang Man , Kim, Hea Ok , Chun, Moon Woo , Kim, Hee-Doo and Kim, Joong Hyup(2003) 'Synthesis and Biological Evaluation of Halo-neplanocin A as Novel Mechanism-Based Inhibitors of S-Adenosylhomocysteine Hydrolase', Nucleosides, Nucleotides and Nucleic Acids, 22: 5, 589 — 592

To link to this Article: DOI: 10.1081/NCN-120021961

URL: <http://dx.doi.org/10.1081/NCN-120021961>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Synthesis and Biological Evaluation of Halo-neplanocin A as Novel Mechanism-Based Inhibitors of *S*-Adenosylhomocysteine Hydrolase

Lak Shin Jeong,^{1,*} Hyung Ryong Moon,¹ Jae Gyu Park,¹
Dae Hong Shin,¹ Won Jun Choi,¹ Kang Man Lee,¹
Hea Ok Kim,² Moon Woo Chun,³ Hee-Doo Kim,⁴
and Joong Hyup Kim⁵

¹College of Pharmacy, Ewha Womans University, Seoul, Korea

²Division of Chemistry and Molecular Engineering and

³College of Pharmacy, Seoul National University, Seoul, Korea

⁴College of Pharmacy, Sookmyung Women's University, Seoul, Korea

⁵Korea Institute of Science and Technology, Seoul, Korea

ABSTRACT

Halogenated analogues of neplanocin A were synthesized from the key intermediate **1**, among which fluoro-neplanocin A was found to be novel mechanism-based irreversible inhibitor of *S*-Adenosylhomocysteine hydrolase.

Key Words: Halo-neplanocin A; *S*-Adenosylhomocysteine hydrolase; Mechanism-based inhibitor.

*Correspondence: Lak Shin Jeong, College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea; E-mail: lakjeong@ewha.ac.kr.




S-Adenosylhomocysteine hydrolase (SAH)^[1,2] catalyzes the hydrolysis of *S*-adenosylhomocysteine to adenosine and L-homocysteine. Inhibition of this enzyme accumulates *S*-adenosylhomocysteine, which in turn inhibits *S*-adenosyl-L-methionine dependent transmethylation, resulting in no formation of the capped methylated structure at the 5'-terminus of viral *mRNA*.^[1,2] Thus, SAH has been an attractive target for the development of broad spectrum of antiviral agents.^[3]


Neplanocin A has been recognized as one of the most potent inhibitors of SAH by depleting enzyme-bound cofactor NAD^+ .^[4-6] This inhibition is reversed by the addition of cofactor NAD^+ . In addition to this well-known cofactor depletion mechanism, it is mechanistically hypothesized that neplanocin A may form a covalent bond with a nucleophilic amino acid residue at the active site of the enzyme through a Michael type reaction, but its irreversible action may be easily reversed by the presence of acidic 4'-hydrogen as shown in Sch. 1. Therefore, based on this reversible addition-elimination hypothesis, we wanted to demonstrate the likelihood of this mechanism by designing halo-neplanocin A analogues which may be able to inhibit SAH irreversibly because of no acidic hydrogen at the 4'-position, as illustrated in Sch. 1.

Synthesis of the halo-neplanocin A analogues started from the known key intermediate **1**,^[7] as shown in Sch. 2.

The intermediate **1** was treated with chlorine, bromine or iodine in the presence of pyridine to give the halogenated ketones **2**. Reduction of **2** with sodium borohydride in the presence of cerium (III) chloride gave the allylic alcohols **3**. After mesylation of **3**, the mesylates **4** were condensed with adenine anion in the presence of 18-Crown-6 to yield the protected nucleosides. Treatment of the protected nucleosides with boron trichloride at -78°C afforded the final nucleosides **5**. For the synthesis of the fluoro-neplanocin A (**8**), iodo derivative **3** was protected as *t*-butyldiphenylsilyl ether **6**. Reaction of **6** with *N*-fluorobenzenesulfonimide^[8] followed by deprotection with *n*-tetrabutylammonium fluoride produced the desired vinylfluoride **7**.



Scheme 1. Proposed mechanism for the reversible (neplanocin A, $\text{X} = \text{H}$) and irreversible (fluoro-neplanocin A, $\text{X} = \text{halogen}$) reactions at the active site of SAH.



Scheme 2. Reagents: a) X_2 , CCl_4 , pyridine, 53–70%; b) $NaBH_4$, $CeCl_3 \cdot 7H_2O$, 85–97%; c) $MsCl$, Et_3N , 89–99%; d) adenine, 18-Crown-6, DMF, 40–73%; e) 1 N BCl_3 , CH_2Cl_2 , 50–70%; e) $TBDPSCl$, DMF, 50°C, 97%; f) $n-BuLi$, N -fluorobenzenesulfonimide, $-78^\circ C$, then $n-Bu_4NF$, THF, 63%.

in 63% yield. According to the similar procedure used in the preparation of **5**, vinyl-fluoride **7** was transformed to the fluoro-neplanocin A (**8**).

Inhibition of SAH by neplanocin A and its halogenated analogues, **5** and **8** was measured using pure recombinant enzyme from human placenta. The results showed that compound **8** ($IC_{50} = 0.48 \mu M$) was *ca.* 2-fold more potent than the parent neplanocin A ($IC_{50} = 0.87 \mu M$). However, the chloro ($IC_{50} = 36.46 \mu M$) and bromo ($IC_{50} = 60.17 \mu M$) derivatives were found to be less potent than neplanocin A and iodo derivative ($IC_{50} = 1 mM$) was inactive. It is interesting to note that enzyme inhibitory activity is inversely proportional to the size of the halogen atom, indicating the binding pocket of the halogen atom is very small. The irreversible nature of the inhibition achieved with **8** was demonstrated using dialysis, incubation with NAD^+ or adenosine, and ^{19}F NMR experiment, indicating that fluoro-neplanocin A (**8**) is the mechanism-based inhibitor of SAH that appears to operate by our proposed mechanism.

ACKNOWLEDGMENT

This research was supported by the grant from the Korea Research Foundation Grant (KRF-2001-005-F00022).

REFERENCES

1. Cantoni, G.L. Biological methylation and drug design. In *The Centrality of S-adenosylhomocysteine in the Regulation of the Biological Utilization of*



- S-adenosylmethionine*; Borchardt, R.T., Creveling, C.R., Ueland, P.M., Eds.; Humana Press: Clifton, N.J., 1986; 227–238.
2. Turner, M.A.; Yang, X.D.; Kuczera, K.; Borchardt, R.T.; Howell, P.L. Structure and function of *S*-adenosylhomocysteine hydrolase. *Cell Biochem. Biophys.* **2000**, *33*, 101–125.
 3. Liu, S.; Wolfe, M.S.; Borchardt, R.T. Rational approaches to the design of antiviral agents based on *S*-adenosyl-L-homocysteine hydrolase as a molecular target. *Antiviral Res.* **1992**, *19*, 247–265.
 4. Houston, D.M.; Dolence, E.K.; Keller, B.T.; Patel-Thombre, U.; Borchardt, R.T. Potential inhibitors of *S*-adenosylmethionine-dependent methyltransferases 9. 2',3'-Dialdehyde derivatives of carbocyclic purine nucleosides as inhibitors of *S*-adenosylhomocysteine hydrolase. *J. Med. Chem.* **1985**, *28*, 471–477.
 5. Cools, M.; De Clercq, E. Correlation between the antiviral activity of acyclic and carbocyclic adenosine analogues in murine L929 cells and their inhibitory effect on L929 cells. *Biochem. Pharmacol.* **1989**, *38*, 1061–1067.
 6. Keller, B.T.; Borchardt, R.T. Biological methylation and drug design. In *Metabolism and Mechanism of Action of Neplanocin A – A Potent Inhibitor of S-adenosylhomocysteine Hydrolase*. Borchardt, R.T. Creveling, C.R. Ueland, P.M., Eds.; Humana Press: Clifton, N.J., 1986; 385–396.
 7. Marquez, V.E.; Lim, M.-I.; Tseng, C.K.-H.; Markovac, A.; Priest, M.A.; Khan, M.S.; Kaskar, B. Total synthesis of (-)-neplanocin A. *J. Org. Chem.* **1988**, *53*, 5709–5714.
 8. Taylor, S.D.; Kotoris, C.C.; Hum, G. Recent advances in electrophilic fluorination. *Tetrahedron* **1999**, *55*, 12,431–12,477.

